SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance

DSpace/Manakin Repository

SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance

Citable link to this page

 

 
Title: SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance
Author: Wang, Zhen; Xu, Xiaoshan; Liu, Nan; Cheng, Yingduan; Jin, Weilin; Zhang, Pengxing; Wang, Xin; Yang, Hongwei; Liu, Hui; Tu, Yanyang

Note: Order does not necessarily reflect citation order of authors.

Citation: Wang, Zhen, Xiaoshan Xu, Nan Liu, Yingduan Cheng, Weilin Jin, Pengxing Zhang, Xin Wang, Hongwei Yang, Hui Liu, and Yanyang Tu. 2018. “SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance.” Oncotarget 9 (1): 192-204. doi:10.18632/oncotarget.22773. http://dx.doi.org/10.18632/oncotarget.22773.
Full Text & Related Files:
Abstract: Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor with limited therapeutic options. Glioma stem cell (GSC) is thought to be greatly responsible for glioma tumor progression and drug resistance. But the molecular mechanisms of GSC deriving recurrence and drug resistance are still unclear. SOX9 (sex-determining region Y (SRY)-box9 protein), a transcription factor expressed in most solid tumors, is reported as a key regulator involved in maintaining cancer hallmarks including the GSCs state. Previously, we have observed that silencing of SOX9 suppressed glioma cells proliferation both in vitro and in vivo. Here, we found that SOX9 was essential for GSC self-renewal. Silencing of SOX9 down-regulated a broad range of stem cell markers and inhibited glioma cell colony and sphere formation. We identified pyruvate dehydrogenase kinase 1 (PDK1) as a target gene of SOX9 using microarray analyses. PDK1 inactivation greatly inhibited glioma cell colony and sphere formation and sensitized glioma spheres to temozolomide (TMZ) toxicity. In addition, SOX9-shRNA and PDK1 inhibitor could greatly sensitize GSC to TMZ in vivo. Taken together, our data reveals that SOX9-PDK1 axis is a key regulator of GSC self-renewal and GSC temozolomide resistance. These findings may provide help for future human GBM therapy.
Published Version: doi:10.18632/oncotarget.22773
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787456/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014413
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters